Mitochondria in invading immune cells may harm nerves

Credibility

Interest

Share:2 min read

Key Takeaway

In a mouse model of MS, invading immune cells called monocyte-derived macrophages damage nervous tissue mainly by making harmful mitochondrial reactive oxygen species (mtROS).

What They Found

The researchers compared two types of brain immune cells: microglia (born and living in the brain) and monocyte-derived macrophages (MdMs, immune cells that enter the brain during inflammation). They found MdMs had higher activity in genes linked to oxidative stress and made more reactive oxygen species (ROS), chemicals that can damage cells; think of ROS like sparks that can burn nearby tissue. Surprisingly, a commonly blamed enzyme called NADPH oxidase 2, which makes ROS during cell 'eating' of debris, was not needed for the nerve damage seen in these mice. When the team added an enzyme that specifically neutralizes mtROS inside mitochondria (the cell's energy factories) of MdMs, the mice had milder disease, while doing the same in microglia did not help. Importantly, neutralizing mtROS did not stop MdMs from doing normal tasks like clearing debris, which suggests the benefit came from lowering the harmful sparks without turning off helpful cleanup work.

Who Should Care and Why

People with MS and their caregivers should care because the study points to a specific source of damage: invading immune cells' mitochondria, not the brain's resident immune cells, which could change how we think about treatments. This is like finding that sparks from a visiting worker, not the house's appliances, are causing most of the fire damage; fixing those sparks could protect the house without shutting down normal home functions. Neurologists and MS researchers may use this idea to develop treatments that target mitochondrial ROS in invading immune cells, which could mean fewer side effects than broadly suppressing the immune system. Caregivers might find hope in treatments that protect nerves while allowing helpful immune cleanup to continue, potentially preserving function and slowing worsening. Patients who have active inflammation (new relapses or MRI activity) could be the first to benefit if therapies based on this idea are developed.

Important Considerations

These results come from a mouse model of MS, not directly from people, so we cannot assume the same effect will happen in humans. The study used genetic tools to change only certain cells, which is not how current medicines usually work, so turning this into a safe drug will take more research. Also, while lowering mtROS helped in this study, we need more work to check long-term effects and whether targeting mtROS is safe in real-world patients.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Early Research Treatment Updates MS Progression

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Science immunology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News